Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2012-06-11
Target enrollment:
Participant gender:
Summary
This study is for patients who have been treated with surgical removal of the testes or
hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this
treatment.
PS 341 is a type of drug known as a "proteasome inhibitor." By inhibiting the "proteasome" in
cancer cells, PS-341 alters the way those cells divide). We hope to learn whether this
combination chemotherapy decreases cancer symptoms and tests (prostate specific antigen, also
called PSA), and to determine how frequently serious side effects might occur with this
treatment for this stage of prostate cancer.